| Investigation clouds Sky's ITV stake
SOME of the UK's biggest companies will come to the market this week at the start of the busiest few weeks of the year for corporate results. Oil giant Royal Dutch Shell will set another profits record when it posts full-year results on Thursday. Soaring oil prices mean broker UBS expects a net income figure in the region of £12.22bn, which far exceeds Shell's previous best of £11.67bn set last year. But the performance in the fourth quarter, when profits are likely to be marginally lower, will carry the most interest for investors. Oil prices have eased by 30% since hitting $77 in August, meaning Shell's production record will be brought into focus. It is likely that output fell marginally in the year, following attacks on its production facilities in Nigeria.
12 Tips to Safeguard Your Heart
The holiday season -- those sometimes intense weeks that begin around Thanksgiving and stretch to New Year's Day and beyond -- can be a time of good cheer, brightly lit parties brimming with food and drink, the pleasure of family reunions, and feelings of generosity and peace. It can also be a lonely time or a stressful one, a season of eating, drinking or spending too much. These downsides, along with other factors, contribute to the spike in heart disease deaths during the holidays. Striking a balance between celebration and health can be a challenge for anyone. Heart disease complicates matters a bit. With some advance planning and common sense, you and your heart can come out the other side of the holidays no worse for wear and maybe even better.
What Is It About Winter?
A handful of small studies have hinted that death has its season, and that the season is winter.
Q-Med Has Entered into a Development and Commercialisation ...
STOCKHOLM, Sweden--(BUSINESS WIRE)--Feb 9, 2007 - Q-Med AB (STO:QMED) and Medy-Tox Inc., a South Korean biopharmaceutical company, have today entered into an agreement regarding collaboration with regard to botulinum toxin based biopharmaceuticals. This collaboration will allow Q-Med to develop and commercialise new generations of botulinum toxin products for both esthetic and therapeutic indications. Medy-Tox will support Q-Med with its extensive technology and know-how in the development of botulinum toxin and Q-Med will support Medy-Tox in the establishment of its new facilities. .
|
